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Edited by Horst FeldmannAbstract The internal guiding sequence (IGS) is normally lo-
cated at the 5 0 end of trans-splicing ribozymes that are derived
from the Tetrahymena group I intron, and is required for the rec-
ognition of substrate RNAs and for trans-splicing reactions.
Here, we separated the Tetrahymena group I intron at the L2
loop to produce two fragments: the IGS-containing substrate,
and the IGS-lacking ribozyme. We show here that two fragments
can complex not through the IGS interaction but under the guid-
ance of appended interacting nucleotides, and perform trans-
splicing. The splicing reactions took place both in vitro and in
mammalian cells, and the spliced mRNA product from the self-
assembled ribozyme complex can be translated into functional
proteins in vivo. The splicing eﬃciency was dependent on the
length of appending nucleotides.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tetrahymena group I intron ribozyme can splice itself out of
the RNA transcripts at the 5 0 splice site located in the P1–P2
domain in the presence of Mg2+ (2 mM) and a guanosine
nucleoside as a cofactor [1,2]. The self-splicing reaction re-
quires a uridine at the 5 0 splice site, which forms a critical wob-
ble base pair with a guanine of the 6-base internal guiding
sequence (IGS) [3]. With the truncation of the L1 loop, located
between the 5 0 splice site and the IGS, the remaining 3 0 frag-
ment of Tetrahymena group I intron ribozyme can bind a sub-
strate RNA bimolecularly and perform splicing reactions
analogous to the reaction steps of self-splicing but in trans,
mediated by the interaction between the substrate RNA and
the IGS [4,5]. Extensive biochemical and structural studies
have shed light on the mechanism of the splicing reaction [6–
8], and led to the development of trans-splicing ribozymesAbbreviations: Bla, b-lactamase; CMV, cytomegalovirus; IGS, internal
guiding sequence; PCR, polymerase chain reaction; RT, reverse tran-
scriptase
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doi:10.1016/j.febslet.2006.01.090for targeting and modifying mRNA transcripts in vitro and
in vivo [9–14]. There are examples of trans-splicing ribo-
zymes-mediated repairing of mRNAs transcripts encoding mu-
tant p53 [11], mutant chloride channel [12], and transcripts
associated with myotonic dystrophy and sickle cell anemia in
mammalian tissue culture cells [13,14]. However, biochemical
engineering is needed to improve the in vivo eﬃciency of
trans-splicing ribozymes for eﬃcient RNA repairs and correc-
tions.
We are interested in designing new variants of Tetrahymena
group I intron ribozyme for intermolecular splicing. We began
our eﬀort by examining whether the Tetrahymena group I intron
can be split at diﬀerent sites than the L1 loop but still perform
trans-splicing reactions. Furthermore, it would be very interest-
ing whether a ribozyme without possessing the IGS could carry
out the trans-splicing reaction with a substrate RNA.
We previously reported a ribozyme construct, Rz156, where
the Tetrahymena group I intron ribozyme was inserted into the
coding sequence of the cDNA of the non-secreted TEM-1 b-
lactamase (Bla) [15]. Expression of Rz156 in mammalian cells
resulted transcripts that can self-splice and generate enzymati-
cally active Bla that can be detected in single mammalian cells.
Based on the cis-splicing Rz156, we constructed a trans-splicing
ribozyme derived from Rz156 split at the L1 loop [16]. Because
this system sensitively and conveniently detects the ribozyme
splicing activity both in vitro and in vivo, we used it in this
study to examine whether the engineered Tetrahymena group
I ribozyme can trans-splice in vitro and in vivo (Scheme 1).2. Materials and methods
All mammalian expression vectors were based on pCMV derived
from pDsRed2-N1 (Clontech) with the DsRed cDNA removed. To
construct the plasmid DNA encoding insertion mutants of the reporter
ribozyme Rz156 [15], a linker was introduced into pCMV-Rz156 be-
tween positions 27 and 28, 43 and 44, 95 and 96, or 312 and 313 by
polymerase chain reaction (PCR) mutagenesis. The mutant with inser-
tion at position 43 (pCMV-Rz#111) was constructed by insertion of
KpnI recognition sequence (GGTACC) between positions 43/44 in
group I intron of the pCMV-Rz156. The 5 0 part of the pCMV-
Rz#111 that carried BamHI site inside the fragment was prepared
by PCR using primers containing EcoRI or SalI site and inserted in
EcoRI/SalI site of pCMV to make pCMV-A. Appended RNA se-
quences were ampliﬁed by PCR and ligated into BamHI/SalI site in
pCMV-A to construct pCMV-SA, pCMV-MA, and pCMV-LA. To
prepare pCMV-ZA, pCMV-LA was self-ligated after BamHI/KpnI
digestion. pCMV-B was constructed by self-ligation of the pCMV-
Rz#111 after removal of 5 0 part of the pCMV-Rz#111. pCMV-B
was digested by HindIII/KpnI and self-ligated to make pCMV-ZB.
pCMV-SB, pCMV-MB, and pCMV-LB were constructed by insertionblished by Elsevier B.V. All rights reserved.
Scheme 1. Strategy for modulating the splicing activity of non-IGS-containing Tetrahymena ribozyme via RNA self-assembly. The IGS (GCCGCU)
is located on the substrate. Bla I and Bla II are the 5 0 and 3 0 fragments of Bla mRNA, respectively. The gray bars represent the appended sense and
antisense RNA sequences that are used to mediate the trans-splicing reaction.
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pCMV-SA, pCMV-MA, and pCMV-LA at HindIII/KpnI site of
pCMV-B, respectively. A point mutation (G264A) in pCMV-LBrd
was created by PCR using a primer containing the mutation. pT7-LBr-
del was constructed by deletion of sequence ﬂanked by BglII/NheI site
in Tetrahymena group I intron after replacing pCMV-LB with T7 vec-
tor. A BamHI–KpnI fragment containing appended sequence from
pCMV-LA was ligated in HindIII/KpnI site of pCMV-LB in blunt-
cohesive ligation to prepare pCMV-LBNB. The appended sense–anti-
sense sequences were derived from the following regions of the DsRed
cDNA: nt 61–90 (for SA/SB), nt 61–149 (for MA/MB), and nt 61–259
(for LA/LB, LBrd, LBrdel, and LBNB), where A in the initiation co-
don is numbered as nt 1. All PCR reactions for plasmid DNA con-
struction were done by Pfu Turbo DNA polymerase (Stratagene) to
avoid undesired mutations. The Bla and ribozyme sequences in all con-
structs were conﬁrmed by DNA sequencing.
All in vitro transcription ribozyme fragments were cloned directly
behind the T7 RNA polymerase promoter site in either the pTRIkan
19 or 18 vector (Ambion). 5 0 pTRI primer (GTGACACTATAGAA-
TACACGG) and 3 0 pTRI primer (CACGACGTTGTAAAACGA-
CGG) were used to generate PCR fragments containing each ribozyme
fragment with T7 RNA polymerase promoter site at the 5 0 end of the
PCR fragment. The PCR cycle conditions used were as follows: an ini-
tial denaturing step at 94 C for 5 min; then 35 cycles of 94 C for 45 s,
55 C for 1 min, and 72 C for 90 s. A ﬁnal polymerization step at
72 C for 7 min was performed, followed by 4 C to terminate the reac-
tion. Each PCR product was puriﬁed from a 2% agarose gel with the
GFX DNA puriﬁcation kit (Amersham Biosciences). The DNA con-
centration was quantitated by UV absorbance. All PCR products were
conﬁrmed by DNA sequencing. Using the T7-MEGA shortscript kit
(Ambion), 150–900 ng of each PCR product was used as the DNA
template for in vitro transcription, and incubated at 37 C for 3–4 h.
2 U of DNase I was added to each reaction and incubated at 37 C
for 15 min. The RNA transcripts were puriﬁed by electrophoresis on
8 M urea/3.5% polyacrylamide gel. The gels were stained by 0.05%
toluidine blue and RNA bands were excised, crushed, and soaked in
an elution buﬀer (0.5 M ammonium acetate, 2 mM EDTA, 0.1%
SDS) at 37 C overnight. The slurry was transferred into a Nanosep
MF 0.2 lm ﬁlter (Pall Corporation) and cleared by centrifuge
14000 · g for 10 min. RNAs in the ﬁltrate were ethanol-precipitated
and re-suspended in nuclease-free water. Concentrations were deter-
mined by measuring the absorbance at 260 nm.Each RNA (100 nM) transcribed in vitro was denatured at 95 C for
1 min and pre-equilibrated in the reaction buﬀer (50 mM HEPES, pH
7.0; 150 mM NaCl; 5 mM MgCl2) at 37 C for 2 min. RNAs were
mixed with GTP (100 lM) to start splicing reactions, which proceeded
at 37 C for 3 h. The reaction product was applied to reverse transcrip-
tion by random primer (SuperScript First-Strand Synthesis System for
RT-PCR, Invitrogen) in the presence of 50 mM of L-argininamide to
inhibit splicing during the reverse transcription. After RNase H treat-
ment, the resultant cDNAs were ampliﬁed by the following protocol:
94 C for 5 min, 30 cycles of 94 C (30 s), 58 C (30 s), 72 C (1 min),
and ﬁnal extension step at 72 C for 7 min; primers: RT-1 forward pri-
mer (CAGAAACGCTGGTGAAAG), and RT-2 backward primer
(CGTCAATACGGGATAATACC). PCR products were analyzed
by electrophoresis in 2% agarose gel. The identities of all spliced prod-
ucts were conﬁrmed by sequence analysis.
COS-7 cells were seeded in six-well dishes at a density of 4.0 · 105
per well for 18–24 h before transfection with 4 lg of expression vector
per well by Lipofectamine 2000 (Invitrogen). Forty-eight hours after
transfection, total RNAs were extracted by TRIzol (Invitrogen)
according to the manufacture’s instruction. Before RNA extraction,
EDTA was added to TRIzol at a ﬁnal concentration of 45 mM to in-
hibit the ribozyme activity. After treated by DNaseI (Invitrogen), ex-
tracted RNAs were reverse transcribed by oligo (dT) primer
(SuperScript First-Strand Synthesis System for RT-PCR, Invitrogen)
in the presence of 10 mM of L-argininamide and ampliﬁed by PCR.
To assay Bla activity, COS-7 cells were seeded in 12-well dishes at a
density of 2.0 · 105 per well for 18–24 h before transfection with 1.6 lg
of expression vector per well by Lipofectamine 2000. Forty-eight hours
after transfection, cells were collected by centrifugation at room tem-
perature at 2600 · g for 1 min. After washing the cells in 800 ll of
PBS (GIBCO/BRL), cell pellets were re-suspended in 50 ll of 0.1 M
phosphate buﬀer (pH 7.0). Cell lysates were prepared by three freezing
and thawing cycles (freezing in dry ice/isopropanol for 10 min and
thawing in 37 C water bath for 10 min). The supernatant was recov-
ered by centrifugation at 16000 · g for 2 min at 4 C. Assays were con-
ducted in 96-well black wall microtiter plates. To measure Bla activity,
45 ll of cell lysate and 5 ll of 1 mM CC1 (a ﬂuorogenic substrate for
Bla synthesized in our lab [17]) were mixed in each well. Fluorescence
was measured with 360 nm excitation and 465 nm emission at each
time point in a SAFIRE microplate reader (TECAN, Research Trian-
gle Park). The hydrolysis rates were converted to a unit of nM/min/lg
total proteins by the calibration with the standard curve of coumarin,
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zation against the total lysate protein contents determined by a Brad-
ford assay (Bio-Rad).3. Results and discussion
In looking for an appropriate split site in the ribozyme struc-
ture, we chose sites located either at the junction sites of the
ribozyme structural domains or in the loop region. We postu-
lated that a split site should tolerate structural perturbations
like insertions. We inserted a short sequence of nucleotides
immediately after position 27, 43, 95, or 312 of the group I in-
tron ribozyme of the Rz156, respectively. Those sites were lo-
cated either at the junction sites of the domains or in the loop
region, but all outside the catalytic core. These linker-inserted
reporter constructs were transfected with COS-7 cells indepen-
dently, and RT-PCR assay and enzymatic assay of Bla by CC1
(a ﬂuorogenic substrate of Bla we developed [17]) revealed that
a mutant with an insertion (GGTACC) after position 43 in the
L2 region of the P2 stem–loop displayed an eﬃcient Bla pro-
duction with the same activity as Rz156 (data not shown).
These data indicated that an insertion at this position aﬀects
little on the ribozyme activity. This result was a little surprising
in light of previous studies that nucleotides 44 and 45 of loop
L2 are very sensitive to base substitutions and the L2 loop has
a tertiary contact with the loop in P5 domain [18,19]. It is likely
such an interaction is reserved in our insertion mutant. There-
fore, this mutant was chosen for further engineering.
We split the reporter construct Rz156 between position 43
and 44 of the group I intron sequence to aﬀord two fragments:
the IGS-containing substrate, and the IGS-lacking ribozyme
fragment. Each fragment was cloned into a vector with T7
RNA polymerase promoter to examine whether these RNAs
were able to perform trans-splicing in a test tube. In vitro tran-
scription aﬀorded transcription units, termed ZA (5 0 fragment)
and ZB (3 0 fragment). The gel-puriﬁed RNAs were mixed and
reacted under splicing condition in a test tube to detect any
trans-splicing product – Bla mRNAs. RT-PCR revealed a very
faint band that matched the size of the desired trans-splicing
product (Fig. 1). Apparently, although ZA might be able to
bind ZB through the interaction of the reserved 10 base pairs
to reassemble the P2 domain and thus the whole ribozyme
structure, this interaction was too weak and ineﬃcient in reas-
sembling the ribozyme complex. Indeed, no trans-splicingFig. 1. RT-PCR analyses of in vitro trans-splicing reactions of the assembled
PCR products from trans-splicing reactions. RT, reverse transcriptase; M, Dproduct was detected when we cloned ZA and ZB into a mam-
malian expression vector with the human cytomegalovirus
(CMV) immediate early promoter and SV40 polyadenylation
signal, co-transfected COS-7 cells with the vectors, and puri-
ﬁed total cellular RNA for RT-PCR analysis (see Fig. 2).
The lack of splicing activity of the ZA and ZB mixture
prompted us to investigate whether appended interacting
nucleotides to each fragment at its corresponding end of the
split site would help bring two fragments together and facili-
tate the assembly of the P2 domain and thus the ﬁnal complex
(see Scheme 1). Three diﬀerent lengths of nucleotides (42, 101,
and 211) of sense and antisense sequences were added to the
3 0and 5 0 end of ZA and ZB, respectively. Accordingly, the 5 0
fragments of these constructs were named as SA, MA, LA,
respectively, and the 3 0 fragments as SB, MB, and LB, respec-
tively.
We conducted in vitro trans-splicing experiments to evaluate
whether the self-assembled ribozyme complexes formed and
spliced. Equal amounts (100 fmol) of in vitro transcribed cor-
responding RNA fragments were mixed and incubated under
the splicing condition (Fig. 1). In each case, a correct trans-
splicing product was produced and conﬁrmed by RT-PCR
analysis and sequencing. Sequence analysis revealed that the
top bands with a mass of 600 bp contained both Bla and
ribozyme, which might be the strand-transferring products of
reverse transcription; such RT mediated strand transfer has
been observed previously with retrovirus and human immuno-
deﬁciency virus [20,21]. Therefore, the appearance of this band
indicated the formation of the self-assembled complex. The
middle bands with a mass of 500 bp were consistent with
the pattern of Rz156 cis-splicing construct with which cryptic
splicing could take place [15]. These data consistently sup-
ported that appended base pairings reassembled the ribozyme
complex and reconstituted its splicing activity. Indicated from
the band intensities of the spliced products, of which MA/MB
and LA/LB were higher than that of ZA/ZB and SA/SB, the
splicing eﬃciency appeared to depend on the length of ap-
pended base pairs.
Control constructs, LBrdel and LBNB, were prepared to
evaluate whether the observed RT-PCR products were depen-
dent on the ribozyme activity and appended base pairings.
LBrdel was a mutant of LB but with a deletion of 94 nucleo-
tides (from nt 238 to 331, where the guanosine-binding site is
located). No desired spliced products were observed in the
mixture of LA and LBrdel that lacked the catalytic core ofribozyme complexes. Arrow indicates 177 bp DNA of the expected RT-
NA marker.
Fig. 3. The enzymatic activity assay of COS-7 cells transiently
transfected with indicated constructs. The hydrolysis rates of CC1
were determined from six independent transfections and normalized
against total lysate protein contents in nM/min per lg protein.
Fig. 2. RT-PCR assay of COS-7 cells transiently transfected with indicated constructs. Reverse transcriptase (RT) was present in upper samples but
not in lower. The expected RT-PCR product from trans-splicing reaction (Bla) was as indicated.
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alytic activity was responsible for the spliced products (Fig. 1).
The other control construct, LBNB, carried the same 211
nucleotides of LA and thus should not form a correctly assem-
bled ribozyme complex with LA. Indeed, when it was incu-
bated with LA, no correct splicing occurred, which
conﬁrmed that appropriate RNA/RNA interaction and align-
ment were required for the correct splicing (Fig. 1). The top
band had a mass of 800 bp containing Bla, ribozyme, and
the 211 bp appended nucleotides, likely the strand-transferring
reverse transcription product of an incorrectly assembled com-
plex.
Having demonstrated this assisted assembling of ribozyme
activity in vitro, we asked whether it could take place
in vivo. To do this, we generated mammalian expression vec-
tors for each construct and tested them in COS-7 cells. The
RT-PCR assays of extracted RNAs from transfected cells
showed that co-expression of LA and LB produced the
trans-spliced products at the expected size (see Fig. 2). Se-
quence analysis conﬁrmed the accurate trans-splicing of Bla
mRNA. The correctly trans-spliced product (Bla mRNA)
was also detectable in the co-expression of SA/SB or MA/
MB, the constructs with shorter base-pairing interaction than
LA/LB, but with lower intensity. No spliced product was de-
tected when LA was co-transfected with a ribozyme dead mu-
tant LBrd which carried a single point mutation (G264A) in its
guanosine-binding site of the ribozyme, suggesting that the
spliced production of Bla mRNA was due to the reassembled
ribozyme’s catalytic function. Co-expression of LA and LBNB
did not produce the spliced mRNA of Bla either. Moreover, no
trans-splicing product was detected in a ‘‘mix’’ control, where
cells separately transfected with LA and LB, respectively, were
mixed shortly after lyses, indicating that trans-splicing did not
take place during the RNA extraction and the RT reaction.
These results, together with the results in ZA and ZB, support
that the engineered split ribozymes with appended base
pairings are capable of reassembling and trans-splicing inmammalian cells and that the eﬃciency may depend on the
length of sense–antisense interaction.
Previous reports have shown that the self-splicing products
of group I intron are not translated eﬃciently in mammalian
cells [22]. To investigate whether any functional Bla protein
was translated from the trans-spliced product, we assayed the
enzymatic activity of Bla in cell lysates by CC1 (Fig. 3). The
Bla activity in the lysates of COS-7 cells co-transfected with
SA/SB, MA/MB or LA/LB was readily detectable; the activity
of LA/LB was about 46-fold of that of the controls
(0.93 ± 0.34 vs. 0.02 ± 0.01 nM/min/lg proteins). The Bla
activity of LA/LB was twofold of that from MA/MB, and
19-fold of that from SA/SB, indicating its dependence on the
length of the introduced nucleotide sequence. Consistent with
the RT-PCR results, neither LBrd nor LBNB produced any
Bla activity when co-expressed with LA. These data strongly
suggested that the trans-spliced Bla mRNA from the reconsti-
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enzymatically active.
We have demonstrated here that two separated Tetrahymena
group I intron ribozyme fragments – the substrate fragment
including the IGS, and the ribozyme fragment – can be assem-
bled into a functional complex both in vitro and in mammalian
cells under the guidance of appended interacting nucleotides.
The assembled complex possessed the splicing activity both
in vitro and in vivo. This self-assembled trans-splicing reaction
diﬀers from previously known trans-splicing Tetrahymena
group I intron ribozymes in that the association is not depen-
dent on the IGS [9,13,23].
The observed dependence of the splicing eﬃciency of the
assembled complex on the length of the appended nucleotides
has also been reported for trans-splicing ribozymes [16,24–26].
Although the binding energy of appended 42 bp in SA/SB
would be strong enough for stable complexation, its splicing
eﬃciency was much less than that of MA/MB and LA/LB, sug-
gesting that appended nucleotides may involve more than just
aiding the complex association. Further experiments especially
structural study would help to fully understand the roles of ap-
pended nucleotides during the splicing reaction.
The split site we chose here is located in the middle of the L2
loop, which was reported to be important to the tertiary struc-
ture of the active ribozyme [19]. If no additional nucleotides
are appended to each fragment at the split site, the splicing
activity cannot be reconstituted, and the appending of a cer-
tain length of nucleotides led to the restoration of the splicing
activity. Therefore, the Tetrahymena group I intron ribozyme
may be similarly split at other loop sites and reassembled un-
der the guidance of appended interacting nucleotides.
We appended nucleotides to assemble the ribozyme complex
in our study, and other interacting groups such as proteins, or
small molecules may also be exploited to control the complex
formation. Separated domains of proteins can complement to-
gether with partially or completely restored activity [27,28].
Based on this phenomenon, several enzyme complementation
assays have been developed to monitoring protein folding
and protein–protein interactions [27–29]. This system may thus
be applied to design a similar ribozyme-based assay to detect
these RNA-involved interactions in vitro and in cells.
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